Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 100 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.236 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - bosutinibum - compresse rivestite con film - bosutinibum 400 mg ut bosutinibum monohydricum, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.31 mg, poloxamerum 188, povidonum k 25, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

Euroopan unioni - italia - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leucemia, mieloide, acuta - agenti antineoplastici - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Euroopan unioni - italia - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - tumori stromali gastrointestinali - altri agenti antineoplastici, inibitori della proteina chinasi - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Euroopan unioni - italia - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tubercolosi, resistente ai farmaci multiresistenti - antimicobatterici - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 30 mg, lactosum monohydricum 56.06 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 126 - 189 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 90 mg, lactosum monohydricum 168.17 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 378 - 567 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 180 mg, lactosum monohydricum 336.33 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 756 - 1134 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Euroopan unioni - italia - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumori stromali gastrointestinali - agenti antineoplastici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.